Aimmune Therapeutics Inc (NASDAQ:AIMT) – Equities research analysts at Piper Jaffray Companies issued their Q1 2021 earnings per share (EPS) estimates for Aimmune Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Piper Jaffray Companies analyst C. Raymond forecasts that the biotechnology company will earn ($0.48) per share for the quarter. Piper Jaffray Companies currently has a “Buy” rating and a $60.00 target price on the stock. Piper Jaffray Companies also issued estimates for Aimmune Therapeutics’ Q2 2021 earnings at ($0.35) EPS and Q3 2021 earnings at ($0.20) EPS.
A number of other research analysts have also issued reports on AIMT. Wedbush reiterated a “buy” rating on shares of Aimmune Therapeutics in a research note on Thursday, October 31st. Stifel Nicolaus upgraded shares of Aimmune Therapeutics to a “positive” rating in a research note on Monday, September 16th. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday. Goldman Sachs Group set a $27.00 price target on shares of Aimmune Therapeutics and gave the company a “hold” rating in a report on Friday, October 25th. Finally, Royal Bank of Canada reduced their price target on shares of Aimmune Therapeutics to $50.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Aimmune Therapeutics has a consensus rating of “Buy” and an average price target of $43.11.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.03). During the same quarter last year, the business posted ($0.89) EPS.
Hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. bought a new position in Aimmune Therapeutics during the 1st quarter valued at about $32,000. Tower Research Capital LLC TRC bought a new position in Aimmune Therapeutics during the 3rd quarter valued at about $38,000. Aperio Group LLC bought a new position in Aimmune Therapeutics during the 2nd quarter valued at about $76,000. Bank of Montreal Can lifted its holdings in Aimmune Therapeutics by 336.3% during the 2nd quarter. Bank of Montreal Can now owns 4,363 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 3,363 shares during the last quarter. Finally, Quantamental Technologies LLC bought a new position in Aimmune Therapeutics during the 2nd quarter valued at about $140,000. 78.41% of the stock is owned by hedge funds and other institutional investors.
In other Aimmune Therapeutics news, CFO Eric Bjerkholt acquired 1,550 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, September 18th. The stock was bought at an average cost of $22.57 per share, with a total value of $34,983.50. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 13.75% of the stock is currently owned by company insiders.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
Read More: How does new data get added to a blockchain?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.